Abundant Opportunities within the Russian OTC Market, Invest with Caution when Making the Switch, Suggests Kline
Russia’s rapidly growing over-the-counter market, posting a 12% increase to reach RUB 480 billion (USD 16.4 billion) at the manufacturers’ level in 2011, holds much potential for pharmaceutical companies. Although a slight decrease in growth was observed against the previous year, according to new analysis Emerging Markets Rx-to-OTC Switch: Forecasts and Opportunities by global consulting and research firm Kline & Company, the Russian market remains highly robust compared to the U.S. market’s 2.4% growth and comparable with the neighboring emerging market of China posting 15.0%.